Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Insurers Sue Pfizer Over Coverage for $400 Million Off-Label Marketing Settlement

  • Post author:Sam
  • Post published:February 5, 2018
  • Post category:Drug Industry Daily

Three insurers sued Pfizer to stay off the hook for a $400 million settlement reached by the drugmaker over off-label marketing, claiming the relevant policies had expired. Source: Drug Industry…

Continue ReadingInsurers Sue Pfizer Over Coverage for $400 Million Off-Label Marketing Settlement

FDA Unveils Data Standards Strategy for FY 2018-2022

  • Post author:Sam
  • Post published:February 5, 2018
  • Post category:Drug Industry Daily

CDER and CBER issued a joint data standards strategy on Monday, detailing how the centers will develop and use data standards to review pre- and post-market safety and efficiency data…

Continue ReadingFDA Unveils Data Standards Strategy for FY 2018-2022

Boston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31. Source: BioSpace

Continue ReadingBoston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

The Stunning Golden Parachutes of Juno's $9B Celgene Deal

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

Juno's Hans Bishop will take home $287M after Celgene acquired his company. Source: BioSpace

Continue ReadingThe Stunning Golden Parachutes of Juno's $9B Celgene Deal

GSK, Reckitt are the Only Suitors for Pfizer's $20B Consumer Health Biz

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

Companies including Sanofi, J&J, Nestle have dropped out. Source: BioSpace

Continue ReadingGSK, Reckitt are the Only Suitors for Pfizer's $20B Consumer Health Biz

The 3 Small CRISPR Biotechs That Could Cure 10,000 Diseases

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

A look at three small biotech companies that appear to be leading the CRISPR race. Source: BioSpace

Continue ReadingThe 3 Small CRISPR Biotechs That Could Cure 10,000 Diseases

3 High-Risk Biotechs That Could Pop or Drop in 2018

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

A look at three biotech companies that face make-or-break catalysts this year. Source: BioSpace

Continue Reading3 High-Risk Biotechs That Could Pop or Drop in 2018

Suitors Take Note as Bay Area's Nektar May Be Up for Sale

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements. Source: BioSpace

Continue ReadingSuitors Take Note as Bay Area's Nektar May Be Up for Sale

EyeGate Implodes as Eye Drug Flunks Phase II Test

  • Post author:Sam
  • Post published:February 4, 2018
  • Post category:BioPharma

EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints. Source: BioSpace

Continue ReadingEyeGate Implodes as Eye Drug Flunks Phase II Test

House Republicans Ask Gottlieb for Details on Heparin Imports, Contingency Plans for Shortage

  • Post author:Sam
  • Post published:February 2, 2018
  • Post category:Drug Industry Daily

Leaders of the House Energy and Commerce Committee sent a letter to FDA Commissioner Scott Gottlieb Friday asking him to investigate contradictory data on available supplies of heparin, and explain…

Continue ReadingHouse Republicans Ask Gottlieb for Details on Heparin Imports, Contingency Plans for Shortage
  • Go to the previous page
  • 1
  • …
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • …
  • 610
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.